Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin - PubMed (original) (raw)
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin
Yulia Vugmeyster et al. Clin Immunol. 2004 Oct.
Abstract
Therapeutic administration of efalizumab, a humanized antibody to CD11a, induces a marked but reversible increase of peripheral lymphocytes in psoriasis patients. In this study, 13 patients were treated with 12 weekly subcutaneous doses (2 mg/kg/week) of efalizumab, and all 13 patients had increases in leukocyte counts. This increased white blood cell count was mainly due to a 3- to 4-fold increase in the number of circulating CD3(+) lymphocytes during active treatment. Both naive and memory populations of CD4(+) and CD8(+) lymphocytes in the peripheral blood increased, with the largest increase observed in memory CD8(+) T cells. This CD8(+) memory T cell subset is a prominent T cell population found in psoriatic skin. An increase in Type 1 (IFN-gamma producing) T cells was also observed during treatment. Both components of LFA-1, CD11a and CD18, were downregulated during treatment, and surprisingly the integrins CD11b and beta 7 were similarly reduced. We conclude that efalizumab most likely blocks cutaneous entry of memory CD8(+) T cells, a highly disease-relevant cell population. The relatively smaller increase in naive peripheral blood T cells could be attributed to reduced trafficking of naive T cells.
Similar articles
- Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.
Harper EG, Simpson EL, Takiguchi RH, Boyd MD, Kurtz SE, Bakke AC, Blauvelt A. Harper EG, et al. J Invest Dermatol. 2008 May;128(5):1173-81. doi: 10.1038/sj.jid.5701169. Epub 2007 Nov 15. J Invest Dermatol. 2008. PMID: 18007580 Clinical Trial. - Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, Kagen M, Gilleaudeau P, Lee E, Hunte B, Howell K, Dummer W, Bodary SC, Krueger JG. Guttman-Yassky E, et al. J Invest Dermatol. 2008 May;128(5):1182-91. doi: 10.1038/jid.2008.4. Epub 2008 Jan 31. J Invest Dermatol. 2008. PMID: 18239614 Clinical Trial. - The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B, Böckelmann R, Pommer AJ, Malykh Y, Philipsen L, Gollnick H. Bonnekoh B, et al. Skin Pharmacol Physiol. 2007;20(2):96-111. doi: 10.1159/000097982. Epub 2006 Dec 13. Skin Pharmacol Physiol. 2007. PMID: 17167274 - Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH, Langley RG, Ho V. Shear NH, et al. J Cutan Med Surg. 2006;9 Suppl 1:4-9. doi: 10.1007/s10227-006-0101-3. J Cutan Med Surg. 2006. PMID: 16633862 Review. - [Efalizumab].
Descamps V. Descamps V. Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. doi: 10.1016/s0151-9638(06)70989-9. Ann Dermatol Venereol. 2006. PMID: 17053736 Review. French.
Cited by
- Multiple environmental antigens may trigger autoimmunity in psoriasis through T-cell receptor polyspecificity.
Ishimoto T, Arakawa Y, Vural S, Stöhr J, Vollmer S, Galinski A, Siewert K, Rühl G, Poluektov Y, Delcommenne M, Horvath O, He M, Summer B, Pohl R, Alharbi R, Dornmair K, Arakawa A, Prinz JC. Ishimoto T, et al. Front Immunol. 2024 Mar 8;15:1374581. doi: 10.3389/fimmu.2024.1374581. eCollection 2024. Front Immunol. 2024. PMID: 38524140 Free PMC article. - Human CLA+ Memory T Cell and Cytokines in Psoriasis.
de Jesús-Gil C, Sans-de San Nicolàs L, García-Jiménez I, Ferran M, Pujol RM, Santamaria-Babí LF. de Jesús-Gil C, et al. Front Med (Lausanne). 2021 Oct 29;8:731911. doi: 10.3389/fmed.2021.731911. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34778294 Free PMC article. Review. - Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.
Gao Y, Lu J, Bao X, Yi X, Peng C, Chen W, Zhen T, Shi Y, Xing K, Zhu S, Ding Y. Gao Y, et al. Exp Biol Med (Maywood). 2021 Jun;246(11):1253-1262. doi: 10.1177/1535370221993424. Epub 2021 Feb 27. Exp Biol Med (Maywood). 2021. PMID: 33641447 Free PMC article. - Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality.
Mancuso RV, Casper J, Schmidt AG, Krähenbühl S, Weitz-Schmidt G. Mancuso RV, et al. Br J Pharmacol. 2020 Jun;177(12):2696-2711. doi: 10.1111/bph.14996. Epub 2020 Mar 9. Br J Pharmacol. 2020. PMID: 31985813 Free PMC article. - An Analysis of Trafficking Receptors Shows that CD44 and P-Selectin Glycoprotein Ligand-1 Collectively Control the Migration of Activated Human T-Cells.
Ali AJ, Abuelela AF, Merzaban JS. Ali AJ, et al. Front Immunol. 2017 May 3;8:492. doi: 10.3389/fimmu.2017.00492. eCollection 2017. Front Immunol. 2017. PMID: 28515724 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials